Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Takeda Pharmaceutical Company Limited

< Previous 1 2 3 4 5 6 Next >
U.S. FDA Approves Takeda’s HYQVIA® as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda Announces China NMPA Approval of LIVTENCITY® (maribavir) for the Treatment of Adults With Post-transplant Cytomegalovirus (CMV) Refractory to Prior Therapies
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda Receives Positive CHMP Opinion for HYQVIA® as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda and The New York Academy of Sciences Announce 2024 Innovators in Science Award Winners
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda to Present Data at 65th American Society of Hematology (ASH) Annual Meeting, Demonstrating Continued Commitment to Patients with Hematologic Diseases
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda’s ADZYNMA (ADAMTS13, recombinant-krhn) Approved by U.S. FDA as the First and Only Recombinant ADAMTS13 Enzyme Replacement Therapy for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda Announces Late-Breaking Data from Phase 2b Study of TAK-279, an Investigational, Oral, Once-Daily TYK2 Inhibitor, in Patients with Active Psoriatic Arthritis at American College of Rheumatology Convergence Annual Meeting
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda Announces FY2023 H1 Results; Updates Full-Year Forecasts While Remaining on Track Towards Management Guidance
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage III Hodgkin Lymphoma in Combination with AVD
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda Settles Tax Dispute with Irish Revenue over Break Fee Received by Shire
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda Announces Topline Results of Phase 3 ADMIRE-CD II Trial of Alofisel® (darvadstrocel) in Complex Crohn’s Perianal Fistulas
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda’s Dengue Vaccine Recommended by World Health Organization Advisory Group for Introduction in High Dengue Burden and Transmission Areas in Children Ages Six to 16 Years
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda Provides Update on EXKIVITY® (mobocertinib)
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda Announces Approval of CUVITRU™ Subcutaneous Immunoglobulin in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda Announces FDA Acceptance of NDA Resubmission of TAK-721 (budesonide oral suspension) for the Short-Term Treatment of Eosinophilic Esophagitis (EoE)
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda Commits Over $30 Million in Five New Global CSR Partnerships To Further Drive Health Impact in 92 Countries
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda Announces FDA Acceptance of BLA for Subcutaneous Administration of ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda Announces Positive Topline Results from Phase 2b Study Evaluating TAK-279, a Highly Selective Oral TYK2 Inhibitor, for the Treatment of Active Psoriatic Arthritis
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda Reports Strong First Quarter FY2023 Results, Driven by Growth & Launch Products
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
The New England Journal of Medicine Publishes Data from Phase 2 Study of First Oral Orexin Receptor 2 Agonist TAK-994 in Patients with Narcolepsy Type 1
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Pivotal Phase 3 Data Presented at ISTH 2023 Congress Spotlight TAK-755 Prophylaxis for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda Presents Full Data Set from Phase 3 ADVANCE-CIDP 1 Clinical Trial Investigating HYQVIA® as a Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual Meeting
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda and HUTCHMED Announce Publication of Phase 3 FRESCO-2 Results in The Lancet
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda and HUTCHMED Announce Marketing Authorization Application of Fruquintinib for Previously Treated Metastatic Colorectal Cancer Validated by the European Medicines Agency
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda to Present Oncology Portfolio and Pipeline Data at the 2023 ASCO Annual Meeting and EHA Congress
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda and HUTCHMED Announce New Drug Application (NDA) for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority Review
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
U.S. Food & Drug Administration Grants Priority Review of TAK-755 for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda Delivers Strong Revenue and Profit Growth in FY2022; Updated Capital Allocation Policy Reflects Deleveraging Progress and Confidence in Growth Outlook
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.